Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Down 83.3% in February

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 349,800 shares, a drop of 83.3% from the February 13th total of 2,100,000 shares. Based on an average daily volume of 6,960,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 3.5% of the shares of the stock are short sold.

Petros Pharmaceuticals Stock Down 10.3 %

NASDAQ PTPI opened at $0.09 on Thursday. Petros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $1.67. The company has a current ratio of 0.85, a quick ratio of 0.74 and a debt-to-equity ratio of 1.58. The stock has a market cap of $1.04 million, a PE ratio of -0.02 and a beta of 2.04. The stock’s 50 day moving average is $0.24 and its 200 day moving average is $0.30.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).